Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

<p>Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOX...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Carlotta Antoniotti (15352506) (author)
Awduron Eraill:	Alessandra Boccaccino (15352509) (author), Robert Seitz (15352512) (author), Mirella Giordano (15352515) (author), Aurélie Catteau (15352518) (author), Daniele Rossini (15086287) (author), Filippo Pietrantonio (15035729) (author), Lisa Salvatore (15352521) (author), Kimberly McGregor (15352524) (author), Francesca Bergamo (15352527) (author), Veronica Conca (15352530) (author), Simone Leonetti (15352533) (author), Federica Morano (14937009) (author), Giorgio Papiani (15352536) (author), Emiliano Tamburini (15352539) (author), Maria Bensi (15352542) (author), Sabina Murgioni (15352545) (author), Douglas Teller Ross (15352548) (author), Alessandro Passardi (15352551) (author), Isabelle Boquet (15352554) (author), Tyler J. Nielsen (15352557) (author), Jérôme Galon (15031113) (author), Matthew Gordon Varga (15352560) (author), Brock L. Schweitzer (15352563) (author), Chiara Cremolini (15352566) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Immuno-oncology Biomarkers Gastrointestinal Cancers Colorectal cancer Immunotherapy Biomarkers for immunotherapy Translational Research Tumor Microenvironment Immune cells and the microenvironment
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
gan: Carlotta Antoniotti (15352506)
Cyhoeddwyd: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
gan: Carlotta Antoniotti (15352506)
Cyhoeddwyd: (2025)

Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S10 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S4 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S5 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S7 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Table S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Table S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
gan: Renee Maria Saliby (16426550)
Cyhoeddwyd: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
gan: Sonia A. Patel (15055688)
Cyhoeddwyd: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
gan: Sonia A. Patel (15055688)
Cyhoeddwyd: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
gan: Sonia A. Patel (15055688)
Cyhoeddwyd: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
gan: Sonia A. Patel (15055688)
Cyhoeddwyd: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
gan: Sonia A. Patel (15055688)
Cyhoeddwyd: (2025)

Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S5 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S6 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Supplementary Figure S9 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
gan: Chantal F. Stockem (19663331)
Cyhoeddwyd: (2025)

Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
gan: Zhijun Zhou (14950981)
Cyhoeddwyd: (2025)

Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
gan: Zhijun Zhou (14950981)
Cyhoeddwyd: (2025)

Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
gan: Zhijun Zhou (14950981)
Cyhoeddwyd: (2025)

Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
gan: Zhijun Zhou (14950981)
Cyhoeddwyd: (2025)

Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
gan: Laetitia Collet (21903637)
Cyhoeddwyd: (2025)

Supplementary Data 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
gan: Laetitia Collet (21903637)
Cyhoeddwyd: (2025)

Supplementary Data 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
gan: Laetitia Collet (21903637)
Cyhoeddwyd: (2025)

Supplementary Table 1 from CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
gan: Ye Wei (15136128)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment
gan: Dimitrios N. Sidiropoulos (18491663)
Cyhoeddwyd: (2025)